As of April
2016 the REVISE-Diabesity
Study HAS COMPLETED ONE YEAR and
has one more year to run.
This study is a multi-centre
randomised controlled trial evaluating the effectiveness of
a new device called Endobarrier combined with a GLP-1
(liraglutide) or used alone.
REVISE-Diabesity is funded
by ABCD is supported by the NHS, as one of the National
Institute for Health Research’ (NIHR) Clinical (Diabetes)
Research Network Portfolio Studies.